TMED3抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08880(TMED3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

**Background of TMED3 Antibody**

TMED3 (Transmembrane emp24 domain-containing protein 3), also known as ERGIC-32 or GP25L2. is a member of the TMED family involved in vesicular trafficking and cargo transport between the endoplasmic reticulum (ER) and Golgi apparatus. It plays a role in the formation of COPII-coated vesicles, facilitating selective protein secretion and maintaining cellular homeostasis. TMED3 is characterized by a conserved emp24 domain, which mediates interactions with other trafficking components.

TMED3 antibodies are essential tools for studying the protein's expression, localization, and function. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect TMED3 in various tissues and cell lines. Research has linked TMED3 to diseases such as cancer, where its dysregulation may influence tumor progression, metastasis, or drug resistance. For example, TMED3 overexpression has been observed in certain cancers, correlating with poor prognosis.

Additionally, TMED3 is implicated in neurodegenerative disorders and inflammatory responses, highlighting its diverse roles in cellular physiology. Validated antibodies against TMED3 often undergo specificity checks (e.g., knockout validation) to ensure accurate detection. These antibodies enable researchers to explore TMED3's molecular mechanisms, its interplay with trafficking pathways, and its potential as a therapeutic target.